INOVIO PHARMACEUTICALS, INC. Impairment of Intangible Assets, Finite-lived
INOVIO PHARMACEUTICALS, INC. (INO) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2025-03-18
- INOVIO PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2024-12-31 was $0.00.
- INOVIO PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2024-09-30 was $0.00.
- INOVIO PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2023-12-31 was $0.00.
- INOVIO PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2023-09-30 was $0.00.
- INOVIO PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- INOVIO PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2023 was $1.98M.
- INOVIO PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2022 was $0.00.
- INOVIO PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2021 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $0.00 derived: sum of 2 quarters · filed 2025-03-18 | $0.00 10-K · filed 2025-03-18 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $0.00 derived: sum of 2 quarters · filed 2025-03-18 | $1.98M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.98M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $1.98M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $0.00 derived: sum of 2 quarters · filed 2024-03-06 | $0.00 10-K · filed 2024-03-06 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |